One of the few completed studies showed a significant reduction of vascular endothelial growth factor (VEGF) release in breast cancer surgery for TIVA with a positive trend, but no significant difference in short-term survival [14] (Fig. 1). The gene discussed is VEGFA; the disease is breast carcinoma.